Sorrento receives STTR grant to develop MRSA vaccines
Sorrento Therapeutics will receive a total of $600,000, $300,000 annually for two years as Phase I grant. The company will also receive $1m per year for up to
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.